Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer
07:00am, Friday, 19'th Mar 2021
RESEARCH TRIANGLE PARK, N.C., March 19, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Helen Thackray, M.D., FAAP, to the newly cr
BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon's Analyst Calls
12:01pm, Monday, 01'st Mar 2021
With the trading day about halfway over, the broad markets came roaring back to start out the week.
BioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema
06:31am, Friday, 26'th Feb 2021
The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing the approval of BioCryst Pharmaceuticals Inc's (NASDAQ: BCRX) ORLADEYO (berotralstat)
For investors and media only
Why BioCryst Pharmaceuticals Stock Is Falling Today
02:10pm, Thursday, 25'th Feb 2021
The company's fourth-quarter earnings report did not pass muster.
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2020 Results - Earnings Call Transcript
12:29pm, Thursday, 25'th Feb 2021
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2020 Results - Earnings Call Transcript
BioCryst Short-Sellers Lose Control
08:40pm, Sunday, 21'st Feb 2021
Macerich, along with many other REITs, has seen their share price hammered during Covid. Despite headwinds, Q4-20 rent collections for Macerich and peers has exceeded 90%, as traffic returns to pre-pa
BioCryst to Report Fourth Quarter and Full Year 2020 Financial Results on February 25
07:00am, Thursday, 11'th Feb 2021
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2020 financi
BioCryst to Present Data at 2021 American Academy of Allergy, Asthma & Immunology Annual Meeting
07:15am, Tuesday, 09'th Feb 2021
RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that data on ORLADEYO™ (berotralstat) will be presented at the 2021 Amer
Is it the right moment for investing in BioCryst Pharmaceuticals shares?
04:05pm, Wednesday, 03'rd Feb 2021
In less than several weeks, BioCryst Pharmaceuticals (NASDAQ: BCRX) shares have advanced from $7.2 above $12, and the current price stands around $10.2. According to the latest news, the FDA approved
RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement
BioCryst Shares Slide As Reddit-Induced Rally Peters Out
02:22pm, Tuesday, 02'nd Feb 2021
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares, which had been locked in a trading range since the start of January, broke out of the range Monday and rallied strongly, only to pull back in the
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 02'nd Feb 2021
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
Implied Volatility Surging for BioCryst (BCRX) Stock Options
09:47am, Thursday, 28'th Jan 2021
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
10:32am, Monday, 25'th Jan 2021
BioCryst (BCRX) gets approval in Japan for oral, once-daily Orladeyo 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.
